The timing window for hormone therapy
When you start hormone therapy matters as much as whether you start it. Here is what the research shows, and what it means if you are under 60, over 60, or already on treatment.
The short version
For women who start hormone therapy before age 60, or within 10 years of their last period, the evidence shows a net benefit: fewer fractures, less heart disease, less diabetes, and lower overall mortality, on top of relief from the symptoms that brought them in. That is the current position of The Menopause Society and the major women's health organizations.
Starting for the first time after 60, or more than 10 years past menopause, is a more individual decision. The benefits are still real; some of the risks become more relevant and need to be weighed against them. It is not off the table.
If you started inside the window and are now past 60, there is no rule that says you must stop. Many of the benefits depend on continuing.
What estrogen does for you
Hormone therapy is the most effective treatment for hot flashes and night sweats, and that alone changes sleep, mood, and daily function. But the benefits go well beyond symptoms, and they are the reason timing matters at all. These are the findings from randomized trials and the long-term follow-up of the WHI itself, mostly in women who started before 60.
- Bone. Estrogen is the only therapy that both prevents bone loss and reduces fractures at every site. In the WHI, hip fractures fell by about a third. The Menopause Society lists prevention of bone loss and fracture as a stand-alone reason to prescribe it in women at risk.
- Heart. Women who started in their 50s had fewer heart events, not more. A 10-year Danish randomized trial (DOPS) found roughly half the rate of death, heart attack, and heart failure in women on hormone therapy compared with those not treated. Estrogen keeps vessel walls flexible and slows plaque formation when it is started while the vessels are still healthy.
- Overall mortality. Pooled analyses of women under 60 or within 10 years of menopause show about a 30% reduction in death from all causes.
- Diabetes. New cases of type 2 diabetes dropped by roughly 20% in the WHI, in both the estrogen-alone and estrogen-plus-progestin groups.
- Breast. Estrogen alone (the regimen for women without a uterus) was associated with fewer breast cancers and fewer breast cancer deaths over 20 years of WHI follow-up. This surprised the researchers and still surprises most patients.
- Colon. Estrogen plus progestin reduced colorectal cancer in the WHI.
- Brain and mood. Treating hot flashes and night sweats restores sleep, and that is the single biggest lever on memory, concentration, and mood in midlife. Trials of early-started estrogen show no cognitive harm, and observational data link earlier use with lower dementia rates later.
- Genitourinary. Fewer urinary infections, better bladder control, and relief from vaginal dryness and painful sex. These benefits do not fade with age and are available at any age through low-dose vaginal estrogen.
- Joints, skin, and muscle. Less joint pain, better collagen and skin thickness, and better preservation of muscle mass. Smaller studies, consistent direction.
None of this was known in 2002, and almost none of it reached the public when the later analyses came out. The headline stuck. The data moved on.
Where the window comes from
In 2002, a large study called the Women's Health Initiative (WHI) reported that hormone therapy increased heart disease, stroke, blood clots, and breast cancer. Prescriptions dropped by roughly half within a year, and a generation of women were told to avoid it.
The problem was who was in the study. The average participant was 63 years old, and many were more than a decade past menopause. Very few were the women who actually ask about hormone therapy: those in their late 40s and 50s with hot flashes, night sweats, and sleep that has fallen apart.
When researchers went back and looked at the results by age, the picture changed. Women who started in their 50s did not show the same heart risks. Some analyses showed fewer heart events and lower overall mortality in that group. The increases in risk were concentrated in the women who had started late.
That age-based difference is what clinicians now call the timing hypothesis, and it is the reason the guidance is written around a window.
Why age changes the picture
Estrogen interacts with blood vessels. In vessels that are still healthy and flexible, estrogen appears to help keep them that way: it supports the lining, reduces inflammation, and slows the buildup of plaque. In the first years after menopause, most women's arteries are still in this state.
Over time, without estrogen, plaque can build up and the vessel lining changes. If estrogen is introduced after that process is well underway, it may not have the same protective effect, and in some women it can make existing plaque less stable. The same drug, in a different vascular environment, behaves differently.
That is the heart of it. The therapy didn't change. The arteries it was meeting had.
The window, drawn to scale
Two measurements define the window, and either one counts: your age (under 60) and the time since your final period (under 10 years). A woman who reached menopause at 44 is inside the window until about 54 by the second measure, though many clinicians still treat her favorably up to 60 because she spent extra years without estrogen.
What is actually different after 60
Most of the benefits above hold at any age. What changes after 60 is that a few specific risks, uncommon in younger women, become more relevant when estrogen is started late. The absolute numbers are still small. This is what your clinician is weighing against the benefits, not instead of them.
| Area | Starting inside the window | Starting fresh after 60 |
|---|---|---|
| Bone | Fewer fractures at every site | Still protective; a strong reason to consider it in women with low bone density |
| Heart | Fewer heart events and lower mortality | Protection is not established when started late; oral estrogen may add a small risk in women with existing plaque, which is why transdermal is preferred |
| Diabetes | About 20% fewer new cases | Likely similar; studied less in this group |
| Breast | Estrogen alone: fewer cancers. Estrogen plus progestin: no change for the first 3 to 5 years, then a small increase, roughly one extra case per 1,000 women per year | Same pattern; the choice of progestogen matters more than age |
| Blood clots | Low; patches and gels do not raise it | Baseline risk rises with age; oral estrogen adds to it, transdermal largely does not |
| Stroke | Very low absolute risk; lower still with transdermal | Small increase with oral estrogen and higher doses; low-dose transdermal appears neutral |
| Brain | Better sleep and mood; no cognitive harm; lower dementia rates in observational data | Starting after 65 was linked to a small increase in dementia in the WHI, so late starts are not used for brain protection. Symptom relief and sleep benefits still apply |
| Genitourinary | Fewer infections, better bladder control, comfortable sex | Identical benefit, at any age |
The pattern in the right-hand column is about form, not age alone. Transdermal estrogen (a patch, gel, or spray) goes through the skin and skips the liver, which is where oral estrogen raises clotting proteins. Low-dose transdermal estrogen with a body-identical progesterone is how most of the added risks after 60 are managed, and it is where the conversation usually starts.
Three common situations
You are the woman the research supports. Hormone therapy is the most effective treatment for your symptoms, and starting now is also when it does the most for your bones, heart, and long-term health. The decision is about preference and fit, not safety.
Continuing is reasonable, and for bone and genitourinary health the benefit depends on it. Guidelines are clear that there is no age at which you must stop. Each year, you and your clinician confirm the benefits still hold and that nothing in your health has changed.
This is a real conversation, not a closed door. About 10% of women still have hot flashes in their 70s. If your heart health is good and clots are not in your history, a low transdermal dose may be appropriate. Non-hormonal options also work well here.
Low-dose vaginal estrogen is a different conversation entirely. It stays local, barely enters the bloodstream, and is considered appropriate at any age, including for women with a history of breast cancer.
What if you are 60 right now?
You are fine. The window is not a cliff that you fall off on your birthday. The numbers 60 and 10 come from how the studies grouped women (ages 50 to 59, 60 to 69, and so on), not from anything that changes in your body overnight.
If you are 60 and within 10 years of your last period, the research still describes you favorably. If you are 60 and 12 years out, you are a little past the second measure but still near it, and the conversation is simply more individual: heart history, clotting history, how much your symptoms are costing you. A woman at 61 with healthy arteries and no clots is a very different case from a woman at 61 with two stents, and the guidance expects clinicians to tell them apart.
The further past both markers you are, the more carefully we look. The closer you are to them, the more the decision looks like it would have at 58.
When you can't point to a last period
The window is measured from your final period. A lot of women can't name theirs, because something else stopped the bleeding first. That doesn't close the window; it just changes how we find it. Your age, your symptoms, and sometimes an FSH blood test (hormone labs are not reliable while you are on a birth-control pill) stand in for the calendar.
Hysterectomy, ovaries kept
Your ovaries kept working after surgery, so menopause arrived on its own schedule, just without the signal. Two things are different for you, and both are in your favor. First, you don't need a progestogen; it is only there to protect the uterine lining, and you don't have one. Second, estrogen alone has the gentler risk profile. In the WHI, the women on estrogen alone had no increase in breast cancer over seven years, and a small decrease in some later analyses. Starting fresh after 60 still gets the same individual review, but the table above is kinder for you on the breast line.
Hysterectomy with ovaries removed
This is surgical menopause, and your window opens on the day of surgery. If that happened before age 45, the standard recommendation is hormone therapy until at least the average age of natural menopause (around 51) to protect bone, heart, and brain, unless there is a specific reason not to. The 10-year count starts from the surgery date.
Endometrial ablation
Ablation thins or scars the lining so bleeding stops or becomes very light, but the uterus is still there and small pockets of lining usually remain. That means two things. You still need a progestogen alongside estrogen, because those pockets can still be stimulated. And you can't use bleeding to date menopause, so we date it by symptoms, age, and labs. After an ablation, any new bleeding on hormone therapy is worth reporting, because it is harder to evaluate than usual.
Hormonal IUD
A levonorgestrel IUD (Mirena and similar) often stops periods entirely, which hides your natural timeline. Again, we date menopause by symptoms and labs instead. The useful part: the IUD itself delivers a progestogen to the lining, so it can serve as the progestogen half of hormone therapy while it is in place. If you are already wearing one when symptoms start, estrogen can often be added on top without a second prescription. A copper IUD does not do this; it doesn't contain hormones and doesn't hide your periods.
In every one of these cases the risks after 60 are the same risks described above. What changes is how we locate your window, and whether you need the progestogen at all.
What this means at The Menopause Clinic
We don't treat 60 as a wall. We treat it as the point where the conversation gets more specific. When a woman over 60 asks about starting, we look at the things the research tells us matter: her heart and vascular history, her clotting history, her bone density, how long since her last period, and how much her symptoms are costing her day to day.
From there, the plan usually favors transdermal estrogen at the lowest effective dose, with a clear reason for starting and a plan for when to reassess. For women already on treatment, we review it at every annual visit and adjust rather than stop by default.
Menopause care is all we do, and this is the kind of nuance the headlines never carried. If you have been told you missed your chance, you deserve a second look from someone who read past the first page of the study.
Crystal Burke, FNP-C, MSCP · Clinical Director
This page is general education and does not replace an individual assessment. The positions summarized here reflect The Menopause Society's 2022 Hormone Therapy Position Statement and the age-stratified analyses of the Women's Health Initiative. Cancer screenings stay with your primary care clinician for continuity and monitoring.